Release date: 7 August 2024
Promoter – Financial Intermediary
UNIVERSAL DIAGNOSTICS SALocation
Description
The loan will finance the research and development (R&D) investments of the promoter, a molecular diagnostics company developing blood-based screening tests for the early detection of cancer.
Objectives
The aim is to further advance the promoter's pipeline and bring the products to the medical market.
Sector(s)
- Health - Human health and social work activities
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 92 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB will verify details during the project due diligence.
Status
Under appraisal
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).